GUFICBIO427.80

Gufic Biosciences Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersRPGLIFEUNICHEMLABGUJTHEMORCHPHARMASMSPHARMAINDSWFTLABFDCIOLCPMcap ₹4,290 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations806.7819.8944.0981.1
Other Income2.23.62.72.2
Total Income808.8823.4946.7983.3
Expenses
+ Cost of Materials Consumed341.3344.2425.3443.0
+ Purchases of Stock-in-Trade58.155.464.764.5
+ Changes in Inventories-9.5-24.9-68.9-72.0
+ Employee Benefit Expense109.6127.1151.7157.5
+ Finance Costs15.423.136.636.7
+ Depreciation & Amortisation17.021.130.830.8
+ Other Expenses161.3183.4219.8223.6
Total Expenses693.2729.3860.1884.0
EBITDA145.9134.7151.3164.6
EBIT128.9113.6120.5133.8
Profit
PBT before Exceptional Items115.794.186.599.3
Pretax Income115.794.186.599.3
+ Current Tax26.418.713.717.6
+ Deferred Tax3.25.88.68.3
Tax Expense29.524.522.325.9
Net Income86.169.664.273.5
+ Net Income — Continuing Ops86.169.664.273.5
+ Other Comprehensive Income-0.4-0.10.50.6
Total Comprehensive Income85.769.564.774.0
Minority Interest-0.0-0.0
Per Share
Basic EPS8.746.956.407.32
Diluted EPS8.746.956.407.32
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.10.5
+ Items NOT to be Reclassified to P&L-0.5-0.20.7
+ Tax on Items NOT to be Reclassified-0.00.2
+ Tax on Items NOT to be Reclassified — alt tag-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations8.746.956.407.32
Diluted EPS — Continuing Operations8.746.956.407.32
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit416.8445.1522.8545.7
Gross Margin %51.6754.2955.3855.62
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)115.794.186.599.3
Net Income Adj (tax-effected)86.169.664.273.5
EPS Adj8.746.956.407.32
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital10.010.010.010.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.